Royalty Pharma PLC RPRX
We take great care to ensure that the data presented and summarized in this overview for Royalty Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPRX
View all-
Morgan Stanley New York, NY44.2MShares$1.73 Billion0.1% of portfolio
-
Capital International Investors Los Angeles, CA27.2MShares$1.07 Billion0.16% of portfolio
-
Black Rock Inc. New York, NY23MShares$901 Million0.01% of portfolio
-
Baillie Gifford & CO17.4MShares$680 Million0.48% of portfolio
-
Swedbank Ab Stockholm, V712.2MShares$478 Million0.45% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA12MShares$469 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$428 Million0.01% of portfolio
-
State Street Corp Boston, MA10.3MShares$402 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA7.62MShares$298 Million0.02% of portfolio
-
Caledonia (Private) Investments Pty LTD Sydney Nsw, C37.55MShares$296 Million6.31% of portfolio
Latest Institutional Activity in RPRX
Top Purchases
Top Sells
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Insider Transactions at RPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
18,242
-41.57%
|
$711,438
$39.9 P/Share
|
|
Dec 01
2025
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Indirect |
23,333
-11.29%
|
$909,987
$39.93 P/Share
|
|
Dec 01
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,582
-8.68%
|
$2,713,698
$39.87 P/Share
|
|
Nov 24
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,582
-4.03%
|
$2,644,116
$38.31 P/Share
|
|
Nov 19
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Direct |
3,000
-96.17%
|
$114,000
$38.66 P/Share
|
|
Nov 19
2025
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
132,426
-84.54%
|
$5,032,188
$38.64 P/Share
|
|
Nov 17
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,594
-7.37%
|
$2,714,166
$39.3 P/Share
|
|
Nov 07
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Indirect |
160,000
+43.64%
|
-
|
|
Nov 05
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Grant, award, or other acquisition
|
Direct |
4,626
+9.54%
|
-
|
|
Nov 05
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+0.93%
|
-
|
|
Nov 05
2025
|
George W. Lloyd EVP, Investments & CLO |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+9.54%
|
-
|
|
Nov 05
2025
|
Terrance P. Coyne EVP & CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+9.54%
|
-
|
|
Nov 05
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
36,559
+3.74%
|
-
|
|
Sep 30
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+1.43%
|
$36,645
$35.79 P/Share
|
|
Aug 11
2025
|
Gregory Norden Director |
SELL
Open market or private sale
|
Direct |
33,500
-14.67%
|
$1,206,000
$36.23 P/Share
|
|
Aug 08
2025
|
Gregory Norden Director |
BUY
Conversion of derivative security
|
Direct |
144,660
+38.78%
|
-
|
|
Aug 06
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
21,901
+2.36%
|
-
|
|
Aug 06
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
3,696
+0.56%
|
-
|
|
Aug 06
2025
|
George W. Lloyd EVP, Investments & CLO |
BUY
Grant, award, or other acquisition
|
Indirect |
3,696
+6.6%
|
-
|
|
Aug 06
2025
|
Terrance P. Coyne EVP & CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
3,696
+6.6%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 656K shares |
|---|---|
| Other acquisition or disposition | 530K shares |
| Conversion of derivative security | 605K shares |
| Open market or private sale | 419K shares |
|---|